MG
Therapeutic Areas
Gradient Denervation Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gradient™ Denervation System | Pulmonary Hypertension due to Left Heart Disease (Group 2 PH, including CpcPH) | Early Feasibility Study |
Leadership Team at Gradient Denervation Technologies
DA
David Amaoua
Chief Technology Officer
JM
Julie Messer
Chief Operating Officer
GM
Greg Mann
Chief Financial Officer
SR
Stanton Rowe
Board Director